On-demand Webinar l Nicoya – SPR Analysis of Biomolecules with OpenSPR

Measure Affinity and Kinetics in Real Time from Your Bench
SPR assays are a gold standard in biologics research and development of safe and effective treatments against disease. The data derived from SPR can aid us in better understanding molecular mechanisms while providing inishgt into key signaling pathways and advancing drug development. Join us for this webinar to learn about the advantages of OpenSPR in immunotherapy, plant-based medicines and drug development.
Agenda
- Introduction
- Company overview and Open SPR technology overview
- Open SPR Applications: Immunotherapy, Plant based medicine, Drug development
- Open SPR Operation
- Q&A session
Speaker Information
Dr. Sharel Figueredo, Director of Field Applications
Nicoya Life sciences
Dr. Sharel Figueredo is the Director of Field Applications at Nicoya Lifesciences. She leads a team of field scientists providing applications support globally. She has a PhD from University of California, Irvine and is a bioanalytical chemist with experience in protein detection and characterization. She has worked in biomarker discovery and quantitation in various therapeutic areas. Her expertise in various bioanalytical tools such as chromatography, capillary electrophoresis, microfluidics, mass spectrometry, immunoassays, and most recently SPR.
Featured Product
OpenSPR is user-friendly and has versatile applicability. In smaller companies, the OpenSPR allows researchers to finish off their full experimental workflows at a low cost. In larger companies, the OpenSPR is easily integrated alongside their other assays.
OpenSPR is ideal for:
- Lead Optimization
- Quality control
- Drug discovery
- ValidationFeasibility

Our Partner
Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed. Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments. In less than 3 years, Nicoya has grown rapidly from 14 to 70+ employees who have extensive experience working at the forefront of nanotechnology and biotechnology sectors. Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions.
